Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

PASSIGLIA, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.118
EU - Europa 2.118
AS - Asia 2.017
SA - Sud America 307
AF - Africa 39
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.607
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.069
SG - Singapore 802
RU - Federazione Russa 588
CN - Cina 530
IT - Italia 493
BR - Brasile 240
DE - Germania 226
FI - Finlandia 188
VN - Vietnam 187
HK - Hong Kong 178
GB - Regno Unito 136
PL - Polonia 119
IE - Irlanda 87
FR - Francia 86
JP - Giappone 67
KR - Corea 54
SE - Svezia 48
IN - India 47
TR - Turchia 28
IQ - Iraq 25
RO - Romania 22
UA - Ucraina 22
AR - Argentina 21
CA - Canada 21
ES - Italia 18
BE - Belgio 17
NL - Olanda 17
MX - Messico 16
BD - Bangladesh 15
UZ - Uzbekistan 15
EC - Ecuador 12
VE - Venezuela 12
MA - Marocco 10
CH - Svizzera 9
IR - Iran 9
AT - Austria 8
ID - Indonesia 8
PY - Paraguay 8
PK - Pakistan 7
ZA - Sudafrica 7
CO - Colombia 6
KE - Kenya 6
CI - Costa d'Avorio 5
CZ - Repubblica Ceca 5
LB - Libano 5
PT - Portogallo 5
SA - Arabia Saudita 5
AU - Australia 4
DK - Danimarca 4
MY - Malesia 4
PH - Filippine 4
UY - Uruguay 4
BG - Bulgaria 3
CL - Cile 3
DZ - Algeria 3
EG - Egitto 3
IL - Israele 3
NP - Nepal 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AL - Albania 2
AZ - Azerbaigian 2
GR - Grecia 2
HR - Croazia 2
JM - Giamaica 2
KG - Kirghizistan 2
MD - Moldavia 2
MO - Macao, regione amministrativa speciale della Cina 2
NZ - Nuova Zelanda 2
TT - Trinidad e Tobago 2
AM - Armenia 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CU - Cuba 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
GH - Ghana 1
GP - Guadalupe 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
JO - Giordania 1
KW - Kuwait 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MC - Monaco 1
MN - Mongolia 1
NA - Namibia 1
NG - Nigeria 1
NI - Nicaragua 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
Totale 10.603
Salva come PNG Salva come JPEG
Città #
Fairfield 1.017
Ashburn 674
Singapore 535
Woodbridge 462
Seattle 432
Cambridge 352
Wilmington 351
Houston 345
Chandler 336
Ann Arbor 195
San Jose 186
Hong Kong 171
Moscow 112
Palermo 111
Zgierz 99
Beijing 96
Council Bluffs 92
Helsinki 88
Dublin 82
Medford 82
Nanjing 73
Los Angeles 70
Altamura 69
Santa Clara 59
Ho Chi Minh City 58
Des Moines 57
New York 56
Tokyo 55
Lauterbourg 53
Princeton 53
Lawrence 50
San Diego 48
The Dalles 45
Hanoi 40
Saint Petersburg 35
Dearborn 33
Frankfurt am Main 31
Dallas 30
Ludwigshafen am Rhein 30
Boardman 28
Hefei 28
London 28
Seoul 28
Chicago 26
Kitzingen 25
Phoenix 25
Panama City 23
Buffalo 21
Tianjin 21
Shenyang 20
Jinan 18
Rome 18
Hebei 17
Redwood City 17
Brussels 16
Atlanta 15
São Paulo 15
Warsaw 15
Baghdad 14
Changsha 14
Milan 14
Bremen 13
Da Nang 13
Izmir 13
Jiaxing 13
Nanchang 13
Nuremberg 13
Orem 13
Tulsa 13
Rio de Janeiro 12
Amsterdam 11
Kumar 11
Stockholm 10
Belo Horizonte 9
Manchester 9
Ningbo 9
Seongnam 9
Tashkent 9
Zhengzhou 9
Brooklyn 8
Denver 8
San Paolo di Civitate 8
Casablanca 7
Haiphong 7
Pune 7
Quito 7
Shanghai 7
Buenos Aires 6
Falls Church 6
Joinville 6
Mexico City 6
Munich 6
Abidjan 5
Ankara 5
Cagliari 5
Campinas 5
Edinburgh 5
Falkenstein 5
Hangzhou 5
Jacksonville 5
Totale 7.540
Salva come PNG Salva come JPEG
Nome #
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 341
EGFR inhibition in NSCLC: New findings…. and opened questions? 336
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 310
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations 305
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors 299
Entrectinib: A potent new TRK, ROS1, and ALK inhibitor 280
Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression 272
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients 271
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 263
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 252
Nintedanib in NSCLC: Evidence to date and place in therapy 252
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 250
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 249
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 243
Cancer and the microbiome: Potential applications as new tumor biomarker 235
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? 230
Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer 230
Multisciplinary management of patients with liver metastasis from colorectal cancer 222
The role of targeted therapy for gastrointestinal tumors 222
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis 218
Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway 217
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 215
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 211
Circulating programmed death ligand-1 (cPD-L1) in non-smallcell lung cancer (NSCLC) 207
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 202
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 199
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab 198
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis 198
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 195
Liquid biopsies in lung cancer: The new ambrosia of researchers 192
Improvement in lung cancer outcomes with targeted therapies: An update for family physicians 192
Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC) 184
Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer 177
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 176
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer 174
Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab 165
The role of microRNAs in driving EGFR-TKI resistance in NSCLC cell lines 165
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 162
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 161
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection 161
Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib? 160
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 153
Impact of phospho-Akt expression on the clinical outcome and activity of gemcitabine and Akt inhibitors in pancreatic ductal adenocarcinoma 153
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib 148
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 147
Immune-Biomarkers in Advanced Non-Small Cell Lung Cancer 142
Upfront radiation versus EGFR-TKI: Which is the best approach for EGFR-mutated NSCLC patients with brain metastasis? 140
Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. 139
Corrigendum to "Liquid biopsies in lung cancer: The new ambrosia of researchers" [Biochem. Biophys. Act. 1846(2014) 539-546] 139
Ramucirumab and its use in gastric cancer treatment 138
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials 134
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 107
The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-analysis 97
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review 92
Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis 44
Totale 10.964
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.738
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.738
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021188 0 0 0 0 0 0 0 0 0 0 103 85
2021/2022723 34 137 55 24 33 36 31 61 64 81 56 111
2022/2023967 98 206 23 120 100 137 48 70 85 10 47 23
2023/2024366 13 55 32 22 18 63 46 25 5 11 7 69
2024/20251.104 17 120 106 80 32 46 86 107 50 107 128 225
2025/20263.212 293 112 195 270 376 442 506 430 263 247 78 0
Totale 10.964